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1. Introduction 
Despite the significant development in endoscope technology and in availability of endoscopic 
accessories and the spreading of well structured ERCP training the incidence of ERCP-related 
acute pancreatitis has been little changed in the last three decades. One of the explanations of 
this contradiction may be that post-ERCP pancreatitis occurs nowadays more often in case of 
therapeutic intervention compared to the diagnostic ERCP and the need for solely diagnostic 
ERCP is rapidly declining due to the development of less invasive imaging methods such as 
magnetic resonance cholangiopancreatography (MRCP) and endoscopic ultrasonography 
(EUS). ERCP has become an almost exclusive therapeutic procedure. 
2. Incidence of post-ERCP pancreatitis 
Endoscopic retrograde cholangiopancreatography (ERCP) has the greatest potential for 
complications among the gastrointestinal endoscopic procedures. The most common 
complication is acute pancreatitis with an overall incidence of 2-10 %, which can reach even 
30 % in the presence of certain risk factors. The post-ERCP pancreatitis is most often mild, or 
less commonly moderate, but in about 10% of cases (about 0.4-0.6 % of the procedures 
performed) it is severe and potentially fatal. The mortality rate is about 0.1-0.5 %. 
Furthermore asymptomatic hyperamylasemia occurs in 35-70 % in patients undergoing 
ERCP. The wide interval of the published incidence of pancreatitis can be explained by and, 
depends on the criteria used for diagnosis, the type and duration of follow-up of patients 
involved in the studies, the levels of endoscopic expertise and, the frequency of patients- 
and procedure-related risk factors in the patient population (Cotton et al. 2009).  
3. Definition of post-ERCP pancreatitis 
A transient elevation in the serum amylase concentration without clinical signs of 
pancreatitis is common following ERCP and abdominal pain is also a frequent complaint 
due to distension caused by intestinal retention of air insufflated during the procedure. 
Therefore clear definition is mandatory for exact evaluation of clinical trials, for comparing 
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the results of different publications and for the standardised management in the prevention 
and treatment of ERCP related pancreatitis. 
The current definition is based on an attempt at consensus in 1991 (Cotton et al.). According to 
this proposal post-ERCP pancreatitis was originally defined as „clinical pancreatitis with 
serum amylase at least three times normal at more than 24 hours after the procedure, requiring 
hospital admission or a prolongation of planned admission”. On the basis of this definition the 
widely excepted criteria for the diagnosis of post-ERCP pancreatitis are the followings: 
pancreatic-type abdominal pain and symptoms with onset after ERCP and severe enough to 
require hospital stay or to extend the length of stay of already hospitalised patients, serum 
amylase and/or lipase at least 3 times higher than the upper limit of normal values in 24 hours 
after the procedure, and/or CT/MRI consistent with the diagnosis of acute pancreatitis. 
The severity of attack was graded by the above consensus report as mild, moderate and 
severe. A mild post-ERCP pancreatitis was defined as a need for hospital stay up to 3 days, a 
moderate pancreatitis was defined as a need for hospital stay for 4-10 days, and a severe 
pancreatitis as more than 10 days with a significant complication. The European Society of 
Gastrointestinal Endoscopy (ESGE) guideline recommends a more specific grading system 
of the severity of pancreatitis for the future (Dumonceau et al. 2010). The Atlanta 
classification can also be used for the estimation of severity of the post-ERCP pancreatitis, 
on the basis of the absence or presence of local (documented by CT) or systemic 
complications, independently of the duration of the hospital stay. 
4. Pathophysiology of post-ERCP hyperamylasemia and pancreatitis  
Pathomechanism of post-ERCP pancreatitis is of multifactorial nature, but it has not been 
fully understood yet. It seems to be an inflammatory response to mechanical, hydrostatic, 
thermal, bacterial and chemical insults that results from canulation and other 
instrumentation of the papilla and injection of contrast medium into the pancreatic duct. 
These initiating factors may act independently or in combination. 
Mechanical trauma: repeated cannulation attempts or prolonged manipulation around the 
papillary orifice may cause injury of the pancreatic sphincter or proximal pancreatic duct 
and may lead to mechanical obstruction due to oedema of the pancreatic sphincter or to 
prolonged spasm in patients with sphincter of Oddi hypertension. 
Hydrostatic factor: pressure increase in the pancreatic duct may be related to overinjection of 
contrast medium (parenchymography) or to pancreatic manometry without distal 
aspiration. The consecutive capillary endothelial injury leads to an increase in capillary 
permeability. It has been suggested that this capillary injury might be mediated by oxygen-
derived free radicals. 
Thermal injury: electrocautery current may produce edema of the pancreatic orifice and 
thermal damage of the periampullary acinar cells. Coagulation or blended current causes 
more tissue injury than cutting current. 
Infection: bacterial injury from contaminated endoscope channel or accessories may occur.  
Chemical factor: injection of contrast medium into the pancreatic duct may result in chemical 
injury. High osmolarity contrast agents are thought to play a role in the induction of 
hyperamylasemia, although a meta-analysis (George et al. 2004) could not confirm it. 
Enzymatic factor: intestinal content may activate intrapancreatic proteolytic enzymes. 
The above initiating factors lead to autodigestion due to premature intracellular activation 
of pancreatic proteolytic enzymes, and to release of inflammatory cytokines producing both 
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local and systemic effects (Demols & Deviere 2003, Karne & Gorelick 1999). The severity of 
pancreatitis is determined by the intensity of the inflammatory cascade and systemic 
response. The process itself is believed the same as for other forms of acute pancreatitis.  
5. Risk factors of ERCP related pancreatitis  
Stratification of patients into low or high risk categories is important pre-investigational 
information to take the potential benefit and risk of procedure into account, to consider 
patient referral to a tertiary centre, and for selection of prophylactic measures. A number of 
risk factors acting independently or in combination have been identified. They can be 
categorised as patient related, procedure related, and investigator related risk factors. 
5.1 Patient related risk factors 
A multivariate analysis of prospective studies found as significant patient-related risk 
factors the followings: young age, female gender, suspected sphincter of Oddi dysfunction, 
previous post-ERCP pancreatitis, recurrent acute pancreatitis, and lack of evidence of 
chronic pancreatitis (Freeman & Guda, 2004). The European Society of Gastrointestinal 
Endoscopy (ESGE) guideline further differentiates between definite and likely risk factors 
based on the strength of evidence from prospective studies (Dumonceau et al., 2010) (Table 
1.). These risk factors can act synergistically, putting patients at high risk for post-ERCP 
pancreatitis. 
 
Definite risk factors 
   Suspected sphincter of Oddi dysfunction 
   Female gender 
   Previous pancreatitis 
Likely risk factors 
   Younger age 
   Non-dilated extrahepatic bile ducts 
   Absence of chronic pancreatitis 
   Normal serum bilirubin 
Table 1. Patient-related risk factors of post-ERCP pancreatitis (Adapted from ref. 
Dumonceau et al., 2010) 
The association of these predictors to post-ERCP pancreatitis proved to be the strongest in 
patients with known or suspected sphincter of Oddi dysfunction with a complication rate of 10-
30 %. All of the risk factors are independently important, but they may have a cumulative 
effect. In a prospective multicentre study (Freeman et al. 2001) the highest risk (42%) was 
found in the following combination of the predictors for post-ERCP pancreatitis: female 
patients, normal serum bilirubin level, suspected sphincter of Oddi dysfunction, and 
difficult bile duct cannulation. It can be postulated that a prolonged pancreatic sphincter 
spasm may be an important common factor in the induction of pancreatitis in the group of 
patients with increased risk for post-ERCP pancreatitis, and that this group of patients have 
a lower threshold for developing pancreatitis after ERCP.  
The higher risk in younger age might depend on the lack of age-related atrophy of the 
pancreatic glands and on the higher prevalence of sphincter of Oddi dysfunction in young 
people, predominantly in females. Similarly to the aging, the protective role of chronic 
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pancreatitis can be explained by atrophy and decreased enzymatic activity. Patients with 
normal serum bilirubin and non-dilated stonefree bile ducts reported as predictors for developing 
post-ERCP pancreatitis may also have sphincter of Oddi dysfunction not having been taken 
into consideration in the diagnosis, especially regarding patients complaining also biliary 
pain. A history of acute pancreatitis independently of the etiology is the second most 
important risk factor after sphincter of Oddi dysfunction, and it should be taken into 
consideration before planning an ERCP.  
5.2 Procedure related risk factors 
Procedure-related risk factors are similarly important as patient-related factors in 
determining the incidence and severity of post-ERCP pancreatitis (Fig 1.). Various 
procedures are associated with higher risk of post-ERCP pancreatitis (Table 2.), most of 
them documented by multivariate analyses. For example role of papillectomy has not been 
analysed, but it can be considered as a definitive risk factor on the basis of prospective 
studies. 
 
Definite risk factors 
   Pancreatic duct cannulation and contrast injection 
   Multiple attempts of cannulation 
   Precut sphincterotomy 
   Endoscopic papillectomy 
Other risk factors 
   Balloon dilation of the sphincter 
   Sphincter of Oddi manometry 
   Pancreatic sphincterotomy 
   Pancreatic brush cytology 
   Failure to clear bile duct stones 
   Difficult or failed cannulation 
Table 2. Procedure-related risk factors of post-ERCP pancreatitis 
Repeated attempts at cannulating, also without pancreatic duct contrast injection is associated 
with high incidence of pancreatitis. This fact supports that papillary edema and sphincter 
spasm, rather than hydrostatic ductal and contrast agent injury are the major factors in the 
induction of post-ERCP pancreatitis. The risk rate seems to progressively increase with the 
number of attempts. More than 10 cannulation attempts can increase the risk of pancreatitis 
about 15-fold (Testoni et al. 2010).  
The contrast injection itself can induce pancreatitis due to hydrostatic injury from pancreatic 
duct overfilling, which is the most pronounced in cases of parenchymography. The use of 
lower ionic contrast agents does not result in lower frequency of pancreatitis than that of the 
conventional ones. 
Pre-cut sphincterotomy is associated with a threefold increase of post-procedure pancreatitis, 
however the risk is likely mainly investigator dependent and seems to be lower in experts 
hands. Moreover, early pre-cut may be safer than delayed pre-cut performed after multiple 
cannulation attempts. The overall risk of pancreatitis after pre-cut sphincterotomy is less 
than after repeated attempts at standard cannulation. Out of the two techniques of needle 
knife precut, fistulotomy where the precut is separate from the papillary orifice, seems to be 
accompanied with less pancreatitis than precut starting at the papillary orifice 
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(Mavrodiannis et al. 1999), although high level evidence fails to support the preference of 
fistulotomy.  
 
 
Fig. 1. Endoscopic retrograde cholangiopancreatogram of a young woman with gallbladder 
stones. Non-dilated bile ducts, young age, and female gender represent patient related risk 
factors, and contrast injection into the pancreatic duct a procedure related risk factor for 
post-ERCP pancreatitis 
Pancreatitis occurs after endoscopic papillectomy performed like a snare polypectomy using a 
side-viewing duodenoscope in 15-20 %. Therefore papillectomy (ampullectomy) should 
perform only by well-trained and experienced endoscopists. The incidence and severity of 
this complication can be significantly reduced by prophylactic pancreatic duct stenting 
(Wong, 2004). Pancreatitis caused by stenosis of the pancreatic duct orifice can also be a late 
complication after papillectomy (Norton et al., 2002).  
Biliary sphincterotomy itself is not associated with an increased risk of pancreatitis. 
Currently the use of pure cut current is advisable, because it causes less tissue injury and 
edema than coagulation current. On the contrary to biliary sphincterotomy balloon dilatation 
of the intact biliary sphincter has been associated with a high incidence of pancreatitis, 
therefore its use is not advisable in the presence of patient-related risk factors, especially in 
patients with sphincter of Oddi hypertension. Large diameter biliary stent without 
sphincterotomy can also induce pancreatitis due to compression of the pancreatic sphincter 
(Tarnasky et al., 1997). On the contrary, biliary-stent exchange in sphincterotomised patients 
causes less-frequent pancreatitis compared to other ERCP procedures (Cotton et al. 2008).  
Sphincter of Oddi manometry using standard perfusion catheter is associated with a 
substantial incidence of pancreatitis. The risk can be significantly reduced by using modified 
triple lumen catheter with simultaneous aspiration or by using a microtransducer catheter. 
In two randomised controlled studies the incidence of post-ERCP pancreatitis was found 
using the alternative catheters in comparison with the standard perfusion catheter 3.0% vs. 
23.5 % and 3.1% vs. 13.8 % (Sherman et al. 1990, Wehrmann et al. 2003).  
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Pancreatic sphincterotomy was associated with high risk of pancreatitis in a recent prospective 
multicentre study only in univariate analysis (Testoni et al., 2010), in agreement with some 
earlier reports (Freeman et al., 2001, Cheng et al. 2006). As independent risk factor proved 
have to been only minor papilla sphincterotomy. 
What other procedure risk factors concerns, pancreatic brush cytology can cause pancreatitis 
due to edema in consequence of mechanical trauma of the pancreatic duct. In case of failure to 
clear the bile duct during ERCP residual stones can induce biliary pancreatitis. 
5.3 Investigator related risk factors 
Data about a potential relationship between post-ERCP pancreatitis incidence and 
endoscopist’s experience in the technique defined as annual case volume (the median 
number of ERCPs per endoscopists/year) are conflicting. Endoscopist’s inexperience and 
trainee participation may be associated with a higher incidence as it was shown in some of 
the studies, while others could not confirm it. This might be explained by the fact that in 
high-volume centres there are more patients with high risk for potential post-ERCP 
pancreatitis and larger number of procedures at higher degree of difficulty.  
6. Prophylaxis of ERCP related pancreatitis 
6.1. Mechanical techniques 
6.1.1 Pancreatic stent placement 
The purpose of placing a temporary pancreatic duct stent is to sustain the pancreatic 
outflow in the face of relative obstruction due to edema and sphincter of Oddi spasm caused 
by manipulations of the papilla. A meta-analysis of eight randomized controlled trials 
demonstrated that short term pancreatic stent placement reduces the incidence of post-
ERCP pancreatitis (Mazaki et al 2010) (Fig. 2.). Sofuni et al (2007) found significant benefit of 
stent placement only in patients at high risk for pancreatitis, and it seems to be not cost-
effective in patients at average risk (Das A et al. 2007). Therefore, the use of prophylactic 
pancreatic stenting is generally proposed only for patients who are at high risk for 
developing pancreatitis after ERCP. Similar standpoint is represented also in the 
recommendation of the ESGE guideline (Dumonceau et al. 2010). 
 
 
Fig. 2. The effect of pancreatic stent placement on the incidence of post-ERCP pancreatitis 
according to meta-analysis (Mazaki et al. 2010) 
Post-ERCP 
pancreatitis 
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What kind of plastic stent should be used? 3 mm long 3 -5 Fr straight polyethylene plastic 
stents without internal flanges (for promoting of spontaneous elimination in few days 
following the insertion) and with one or two external flanges (for preventing proximal 
migration) are recommended for prophylactic purpose (Fig.3). Stents of 3-Fr and 5-Fr in 
diameter proved to be similarly effective, but the insertion of 5-Fr stents seems to be easier 
and faster (Zolotarevsky et al. 2011).  
 
 
Fig. 3. Pancreatic stent without internal flanges 
The stent migrates spontaneously into the duodenum within two weeks in most of the cases. 
Within 5 to 10 days after the stent insertion an X-ray control and, when the stent is in place 
yet, endoscopic stent removal is recommended because of the risk of stent-induced damage 
to the pancreatic duct. Adverse events including pancreatitis following stenting of the main 
pancreatic duct occur in 4.2-4.6 %, but the incidence of pancreatitis after failed cannulation 
attempts may reach even 65 % (Freeman et al. 2004). Therefore this is a technique for 
experienced endoscopist.  
6.1.2 Pancreatic guide wire placement for facilitation of bile duct cannulation 
Data about the effectiveness of pancreatic guide wire placement in the prevention of post-
ERCP pancreatitis are still controversial. In patients with difficult bile duct cannulation 
successful biliary cannulation can be achieved by pancreatic guide wire-assisted technique 
in more than 70% of the cases (Dumonceau et al. 2010). If this method is used, a pancreatic 
stent should be placed for prophylaxis of pancreatitis (Fig 4.). For the same reason 
pancreatic stenting can be useful also in cases in which biliary cannulation remains 
unsuccessful. 
6.1.3 Guide wire-assisted deep biliary cannulation 
Insertion of 0.035-inch diameter guide-wire into the papilla directly or advancing the guide-
wire through the sphincterotome inserted into the papilla for deep biliary cannulation 
reduces the risk of post-ERCP pancreatitis due to promotion of selective primary 
cannulation. This method may namely diminish traumatic injury to the pancreatic duct and 
hydrostatic pressure increase associated with injection of contrast material. Therefore, the 
guide wire-assisted technique is advised for deep biliary cannulation by the ESGE guideline 
(Dumonceau et al. 2010). However, in a prospective randomised trial this technique was 
associated with a lower rate of post-ERCP pancreatitis only with the exception of cases 
where the technique was performed in patients with sphincter of Oddi dysfunction or 
where unintentional pancreas guide wire cannulation occurred (Lee et al 2009).  
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Fig. 4. A case of difficult bile duct cannulation. Following pancreatic guide wire-assisted 
technique pancreatic stent was placed for prevention of post-ERCP pancreatitis 
6.2 Pharmacological agents 
Several agents have been tested experimentally and in clinical trials for potential efficacy in 
the prevention of ERCP induced pancreatitis. Chemoprevention studies have targeted the 
following mechanism of action: reduction of pancreatic secretion, prevention of intra-acinar 
trypsinogen activation, interruption of inflammatory cascade, relaxation of sphincter of 
Oddi, and prevention of infection. The majority of the investigated pharmacological agents 
appeared promising in initial randomised single-centre clinical studies however, conflicting 
results were obtained from larger multi-centre trials (Table 3.). 
 
Drug  Efficacy  
Somatostatin  
Octreotide 
Gabexate mesilate 
Ulanistatin 
Nitroglycerin 
Nifedipin 
Lidocain spray 
Epinephrine spray 
Botulinum toxin intrapapillary 
Ceftazidime 
N-acethylcysteine 
Beta-carotene 
Allopurinol 
Glucocorticoids 
Pentoxifylline 
Semapimod  
Acethylhydrolase 
Indomethacin  
Diclofenac  
Conflicting data 
Conflicting data 
Conflicting data 
Conflicting data 
Conflicting data 
No 
No 
No 
No 
Need for more trials  
No 
No 
Conflicting data 
No 
No 
No 
No 
Yes, but need for more trials 
Yes, but need for more trials 
Table 3. Medications tested for prophylaxis of post-ERCP pancreatitis 
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6.2.1 Reduction of pancreatic enzyme secretion  
Somatostatin and its long-acting analogue ocreotide affect the exocrine function of the 
pancreas directly by reducing the secretion of digestive enzymes and indirectly by 
inhibiting the production of secretin and cholecystokinin. According to a meta-analysis 
pooling the data from ten high-quality randomised controlled trials it can be concluded, that 
somatostatin did not influence the overall incidence of post-ERCP pancreatitis (Dumonceau 
et al. 2010). Although a significant risk reduction of post-ERCP pancreatitis was found in 
four randomised controlled trial, when somatostatin was administered in continuous 
infusion for longer than 12 hours, and in two studies, when somatostatin was given as a 
single bolus, the question is yet open, weather using specific dose-schedules somatostatin 
might be more efficacious (Arvanatidis et al. 2004).  
Concerning the long-acting somatostatin analogue ocreotide the same conclusion can be 
drawn based on an ad hoc meta-analysis of eight randomised controlled trials (Dumonceau 
et al. 2010). Octreotide can reduce the ERCP-induced hyperamylasemia, but this effect can 
only be shown, if endoscopic sphincterotomy is simultaneously performed (Tulassay et al. 
1997). Octreotide increases namely the tone of the sphincter of Oddi, and therefore this 
partial beneficial effect of the reduced enzyme secretion may be effective only with 
sphincterotomy together. Some data suggest that the effect of octreotide may be dose-
dependent and more than 0.5 mg of octreotide may be beneficial (Zhang Y et al. 2009), but it 
should yet be clarified in future studies. 
6.2.2 Protease inhibitors 
Antiprotease agents were tested for prophylaxis of post-ERCP pancreatitis with the purpose 
of prevention of intra-acinar trypsinogen activation to trypsin and that of the subsequent 
inflammatory cascade. Gabexate mesilate in six randomised controlled trials, while ulanistatin 
in four randomised controlled trials have been evaluated. Furthermore, the prophylactic 
effect of gabexate with ulanistatin was compared in two clinical trials. The results can be 
summarised by stating that, although there is a small risk reduction, particularly in the 
ulanistatin subgroup, there is no solid evidence that antiprotease drugs significantly 
influence the incidence of post-ERCP pancreatitis. The same conclusion can be drawn from a 
recently published meta-analysis (Seta & Noguchi 2011) on the basis of which it can be 
stated that the primary studies were not of high quality enough to come to the proper 
consequences. Nevertheless, protease inhibitors are costly.  
6.2.3 Sphincter relaxants 
Nitroglycerin (glycerine trinitrate) proved to be effective in some reports, but ineffective in 
others. Based on two meta-analyses (Bang et al. 2009, Shao et al. 2010) of pooled data from 
five randomised controlled trials it can be concluded that nitroglycerin administered orally 
or sublingual may reduce the incidence of post-ERCP pancreatitis, but transdermal 
nitroglycerin is ineffective. The use of nitroglycerin is often associated with transient 
hypotension and headache, therefore the ESGE guideline does not recommend its routine 
use in the prophylaxis of post-ERCP pancreatitis (Dumonceau et al. 2010). 
Nifedipin was also tested, because calcium channel blockers have proved to be effective in 
the prevention of experimental pancreatitis. In clinical trials, however, nifedipin failed to 
show a significant effect in the prevention of post-ERCP pancreatitis (Prat et al. 2002). 
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Other drugs (lidocaine spray, epinephrine spray, Botulinum toxin injected intrapapillary) 
tested with the intention of reducing the sphincter of Oddi pressure failed to show any 
efficacy (Gorelick et al. 2004, Matsushita et al. 2009, Schwartz et al. 2004). 
6.2.4 Antibiotics 
There is only a single study evaluating the ceftazidime for prophylaxis of post-ERCP 
pancreatitis. This antibiotic was given in a dose of 2 g intravenously 30 min prior to the 
investigation and a significant reduction in the incidence of post-ERCP pancreatitis was 
observed (Raty et al. 2001). Further data are necessary to establish the real place of 
antibiotics in the prevention of ERCP-related pancreatitis.  
6.2.5 Antioxidants 
The following antioxidant agents were investigated for prevention of ERCP related 
pancreatitis: N-acetylcysteine (Katsinelos P. et al. 2005), beta-carotene (Lavy et al. 2004) and 
allopurinol. The free radical scavenger N-acetylcysteine and beta-carotene failed to show any 
beneficial effect. Allopurinol is a xanthine oxidase inhibitor and an antioxidant with 
antiapoptotic property. Four randomised clinical trials dealing with its effect in the 
prevention of post-ERCP hyperamylasemia and pancreatitis were published. Three of them 
reported negative outcomes but in two studies allopurinol proved to be effective in the 
reduction of the incidence of hyperamylasemia, and in one of them also in that of acute 
pancreatitis, particularly in patients submitted to high risk procedures (Martinez-Torres et 
al. 2009). Allopurinol was administered orally in a dose of 300 mg at 15 and 3 hours before 
ERCP. 
6.2.6 Antiinflammatory drugs 
Several agents acting by interruption of the inflammatory cascade were tested. 
Glucocorticoids do not reduce the incidence of post-ERCP pancreatitis according to a meta-
analysis based on six randomised controlled trials (Bay et al. 2008). Similarly to 
glucocorticoids pentoxifylline, semapimod, and acethylhydrolase (a recombinant platelet-
activating factor) all proved to be ineffective. Interleukin-10 reduced the incidence and 
severity of post-ERCP pancreatitis in an initial study (Deviere et al. 2001), but further trials 
could not confirm its effectiveness. As suggested by observational and animal studies, 
heparin has also an anti-inflammatory effect, inhibit the activity of pancreatic proteases and 
improves pancreatic circulation, but in clinical randomised controlled trials neither 
unfractionated heparin (Barkay et al. 2008), nor low molecular-weight heparin (Rabenstein T 
et al 2004) proved to be effective in the prophylaxis of post-ERCP pancreatitis. 
Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit phospholipase A2 which has an early 
role in the inflammatory cascade in acute pancreatitis. Inhibition of phospholipase A2 
results in suppression of several important classes of proinflammatory lipids 
(prostaglandins, leukotriens, platelet-activating factor). Furthermore, NSAIDs inhibit 
neutrophyl-endothelial cell attachment. Indomethacin followed by diclofenac is the most 
potent NSAID with regard to phospholipase A2 inhibition. Indomethacin has shown to 
decrease the mortality of experimental pancreatitis in animals (Wildenhain et al 1989). Four 
prospective randomised controlled clinical studies have been published until now that 
compared rectally administered indomethacin or diclofenac vs. placebo (Murray et al. 2003, 
Sotoudehmanesh R et al. 2007, Montano Loza et al. 2007, Koshbaten M et al. 2008) (Fig. 5.). 
www.intechopen.com
 
Endoscopic Retrograde Cholangiopancreatography (ERCP) Related Acute Pancreatitis 
 
207 
On the basis of three meta-analyses using the data of these studies rectally administered 
indomethacin and diclofenac in a dose of 100 mg proved to be effective in the decrease of 
incidence of post-ERCP pancreatitis (Elmunser et al. 2008, Zheng et al. 2008, Dai et al. 2009). 
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(RCT: randomised controlled trial)  
Fig. 5. Incidence of post-ERCP pancreatitis: rectally administered NSAIDs versus placebo. 
The reduction seems to be similar regardless of the degree of the risk (Zheng et al. 2008). 
Limitation of the original studies is the small number of the trials performed only in three 
countries. Therefore some scepticism related to the clinical efficacy of NSAIDs in the 
prophylaxis of post-ERCP pancreatitis exists, all the more because several agents tested 
before have shown promise in early single-centre studies, but the results were disappointing 
in larger multicentre randomised controlled trials. Furthermore it has to be mentioned that 
diclofenac administered intramuscularly or orally did not proved to be effective in lowering 
the rate of post-ERCP pancreatitis significantly (Cheon et al. 2007, Senol et al 2009). Further 
multicentre controlled studies are awaited for confirmation of the promising results of the 
foregoing trials. Nevertheless NSAIDs in a single dose are relatively safe, cheap, and easy to 
use. Therefore 100 mg of indomethacine or diclofenac administered rectally immediately 
before or after ERCP is routinely recommended. This standpoint is reflected also in the 
ESGE guidelines (Dumonceau et al. 2010). 
6.3 Post-procedure management (Follow-up after ERCP) 
Post-ERCP pancreatitis is an unforeseen complication but it can be predicted by measuring 
the serum amylase concentration at 2-4 hours after the procedure. It should be taken into 
account, however, that hyperamylasemia without pancreatitis following ERCP is well 
recognised and abdominal discomfort for some hours after ERCP due to intestinal 
distension by air insufflated during the investigation is a commonly occurring symptom, in 
particular in patients with functional gastrointestinal dysfunction. It is advisable to restrict 
oral intake of water for four hours and until serum amylase value is available. Serum 
amylase concentration less than 1.5 times the upper limit of normal value almost excludes 
post-ERCP pancreatitis and the patient can be discharged on the day of ERCP. For patients 
with four hours serum amylase levels more than twice the upper limit, with ongoing 
p=0,01 p=0,034 p<0,0 1 
7/110 
p<0,049 
 7/221 
15/221 4/75 
 2/75 
2/50 
13/50 
 20/456 
 57/456 
17/110 
p<0,0001  
OR: 0.46 
95% CI: 
0.32-0.65 
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abdominal pain / tenderness or fever, fasting and parenteral fluid replacement is 
recommended. The same policy is advised in the presence of any risk factor of post-
procedural pancreatitis at least for 24 hour after ERCP. Further management is depending 
on the 24 hour serum amylase level and clinical signs of pancreatitis. 
6.4 Principles of prevention and reduction of severity of ERCP-induced pancreatitis 
Following factors listed below should be considered when indicating and performing ERCP. 
1. Because post-ERCP pancreatitis can be severe, life-threatening or even fatal, careful and 
adequate patient selection is one of the most important and the most effective 
preventive measures. ERCP should not be performed when the indication is not clear or 
the procedure is unlikely to benefit the patient. In borderline indications and when the 
aim of ERCP is solely diagnostic, non-invasive imaging methods, magnetic resonance 
cholangiopancreatography (MRCP) and endoscopic ultrasound should be performed 
first. Endoscopists should always take a risk-benefit analysis with knowledge of the 
identified patient related risk factors, when deciding whether to perform an ERCP. 
2. Referral of patients at high risk for post-ERCP pancreatitis to a great volume specialist 
centre should be considered.  
3. Minimal use of contrast material, avoidance of repeated attempts of pancreatic 
cannulation and use of guide wire to gain access or use of dual wire technique can be 
effective measures for prophylaxis in certain cases. 
4. Risk related ERCP techniques should be avoided when possible. 
5. Pharmacological prophylaxis with periprocedural rectal administration of NSAIDs 
(indomethacine or diclofenac) as a cheap, practical and safe method is routinely 
recommended. 
6. Prophylactic placement of short 5 Fr pancreatic stent without inner flanges should be 
strongly considered for patients at high risk for development of post-ERCP pancreatitis. 
7. Early screening for post-ERCP pancreatitis following the procedure and appropriate 
management is also important for the prevention or for reduction of the severity of 
ERCP-related pancreatitis.  
The recommendations above are in concordance with the European Society of 
Gastrointestinal Endoscopy guideline (Dumonceau et al., 2010). 
7. Therapy of post-ERCP pancreatitis 
The treatment of ERCP related pancreatitis is the same as that of the acute pancreatitis of 
other etiologies and it depends considerably on the severity of the pancreatitis. The therapy 
is mainly supportive including fasting, adequate correction of hypovolemia, and 
maintenance of optimal fluid balance, close monitoring for signs of local and systemic 
complications, and adequate pain control. Patients with mild pancreatitis can generally 
begin oral food intake in few days. The outflow of the pancreatic juice can be tried to 
improve with spasmolytics, nitroglycerin or theophyllin. Morphine should be avoided 
because this drug may produce high outflow resistance due to sphincter of Oddi spasm, but 
pethidine / meperidine are allowed if the patient requires it for pain relief. If the efficacy of 
pethidine / meperidine is insufficient, epidural anesthesia is the best choice or fentanyl can 
be given. In cases of severe pancreatitis early nasojejunal feeding can be crucial for the 
maintenance of integrity of the gut mucosal barrier, hereby preventing bacterial 
translocation into the systemic circulation. Translocated pathogen intestinal flora is namely 
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one of the main sources of septic complications. Enteral feeding with appropriate energy 
intake has also a role in the correction of the nutritional imbalance due to the prolonged 
hypermetabolic state in severe acute pancreatitis. Adequate intravenous substitution is also 
very important, likewise early antibiotic prophylaxis in necrotizing pancreatitis – although 
still controversial, and effective antimicrobial treatment of the inflammatory complications. 
Infected pancreatic necrosis and infected pancreatic and peripancreatic fluid collections 
should be treated by surgery or by endoscopic or CT guided intervention. Treatment of the 
systemic complications has to be managed in an intensive care unit with close monitoring of 
the vital functions. 
8. Conclusion 
Acute pancreatitis is the most common and feared complication of ERCP. Post-ERCP 
pancreatitis is severe and potentially fatal in a significant proportion. The incidence rate has 
been little changed over the last decades despite important advances in endoscope and in 
accessory technology. 
The widely accepted criteria for the diagnosis of post-ERCP pancreatitis are serum 
amylase and/or lipase at least 3 times higher than the upper limit of normal values in 24 
hours after the procedure accompanied by new pancreatic-type abdominal pain and 
symptoms and severe enough to require hospital stay or to extend the length of stay of 
already hospitalised patients, and/or CT/MRI consistent with the diagnosis of acute 
pancreatitis. 
The pathomechanism is not fully understood. It seems to be an inflammatory response to 
mechanical, hydrostatic, enzymatic, thermal, microbiological, and probably chemical 
insults that results from cannulation attempts and contrast material injection into the 
pancreatic duct. 
A number of risk factors for developing pancreatitis after ERCP are known, they can 
categorised as patient related, procedure related, and investigator related risk factors. It is 
essential to identify patients at high risk to avoid unnecessary procedures or adopt 
protective technical or pharmacological measures. If patient related risk factors are present, 
first of all it is advised to consider patient’s referral to a specialist centre, or for selection of 
prophylactic measures. In borderline indications non-invasive imaging methods should be 
preferred. Out of procedure related risk factors papillary edema and sphincter spasm are the 
major factors in the induction of post-ERCP pancreatitis. For minimizing the risk of 
pancreatitis during the procedure the following measures should be kept in mind: 
atraumatic manipulation of the papilla, avoidance of repeated pancreatic duct cannulation 
and contrast injection, avoidance of balloon catheter dilatation of the intact sphincter, 
limited use of precut sphincterotomy and pancreatic sphincterotomy, avoiding placement of 
biliary stent through intact papilla, using soft-tipped guide wire to access bile duct, and 
using pure cut electrosurgical current.  
Despite selecting patients and using protective technical measures post-ERCP pancreatitis 
can occur unexpectedly. Therefore prophylactic pharmacological intervention is routinely 
advised by means of rectal indomethacine or diclofenac immediately before or after the 
procedure. The administration of indomethacine and diclofenac in a single dose is safe, 
cheap, and easy and based on the few randomised controlled trials it seems to be effective in 
the decrease of the incidence of post-ERCP pancreatitis. Further randomised controlled trials 
are needed to prove the real efficacy of NSAIDs in the reduction of severe ERCP related 
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pancreatitis. For high-risk ERCPs prophylactic placement of short pancreatic stent proved to 
be beneficial in experienced hands, therefore its use is recommended for few days in these 
cases. 
Careful follow up, early screening for pancreatitis and appropriate management of the 
complication are crucial for the outcome. The treatment of post-ERCP pancreatitis itself does 
not differ from that of the acute pancreatitis of whatever etiology. 
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